P734 Anti-TNFa exposure during pregnancy is not associated with increased infection risk in exposed children during the first year of life

Ďuricová, Dana; Dvořáková, Eva; Koželuhová, Jana; Kohout, Pavel; Mitrová, Katarína; Durilová, Marianna; Zárubová, Kristýna; Hradský, Ondřej; Bronský, Jiří; Hradská, Nora; Bronská, Eva; Machková, Naděžda; Hrubá, Veronika; Bortlík, Martin; Malíčková, Karin; Lukáš, Martin

doi:10.1093/ecco-jcc/jjx180.861

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been argued that high and longlast ing newborn IFX levels might negatively impact newborn health, includ ing infections, al lergies or other im munemediated conditions. In a recent work, Duricova et al compared 69 anti-TNF exposed and 42 unexposed children of mothers with IBD dur ing the 1 st year of their life and found no increased risk in infectious complications in children exposed to anti-TNF in utero [16]. Also, no increased risk of combination ther apy with thiopurines was reported.…”

Section: Ifx Ther Apymentioning

confidence: 99%

Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab

Kolář¹,

Bortlík²,

Ďuricová³

et al. 2018

Gastroent Hepatol

View full text Add to dashboard Cite

Sum mary: Background: In pregnant women with inflammatory bowel disease (IBD), exposure to biologic therapy, especially anti-TNF antibodies, has not been associated with adverse events. However, data on the efficacy and safety of biosimilar infliximab (IFX) in this particular population of IBD patients are lacking. Methods: This retrospective study included 20 women treated with biosimilar IFX (CT-P13) during pregnancy for whom information about pregnancy outcome was available. Data on disease activity, treatment, and pregnancy and newborn outcome were recorded. Cord blood levels of anti-TNF were measured by ELISA. Results: Twenty pregnant women (16 with Crohn's disease and 4 with ulcerative colitis) with a mean age of 28.7 ± 4.1 years were included, 55% of whom were primigravidae. The mean disease duration at the time of pregnancy was 6.0 ± 5.3 years, and 70% of the women had a history of perianal disease. At the time of conception, 30% had active disease and 65% were in remission; one of the women was newly diagnosed with acute severe colitis after conception. Besides this patient, to whom IFX rescue therapy was administered during the first trimester, all women had already been treated with IFX before becoming pregnant, with a mean treatment duration of 2.3 ± 2.7 years. There were 19 live births (mean weight, 3,305 ± 493 g), 18 at term and 1 pre-term (with a low birth weight). One pregnancy ended in spontaneous abortion. Disease activity at conception was associated with lower birth weight (3,549 ± 392 g for those in remission vs. 2,921 ± 390 g for those with active disease; p = 0.0043). Cesarean section was performed in 70% of the women, 79% of whom had a history of perianal disease. No perinatal complications and birth defects were reported, except for a single case of cleft palate. Conclusion: To our knowledge, this is the first report of pregnancy outcomes in women exposed to biosimilar IFX. Under the constraints inherent in the limited sample size, no new safety concerns have so far arisen. Souhrn: Úvod: Biologická terapie těhotných pa cientek s idiopatickými střevními záněty (IBD -inflam matory bowel dis ease) nemá negativní vliv na výsledek těhotenství ani na vývoj plodu. Stále však chybí data o efektivitě a bezpečnosti bio similárního infliximabu (IFX) v této situaci. Metody:Retrospektivní observační studie zahrnovala 20 žen s IBD léčených v průběhu těhotenství bio similárním IFX (CT-P13), u kterých byly k dispozici informace o výsledku těhotenství. Sledovány byly údaje o aktivitě choroby, léčbě, výsledcích těhotenství a data o novorozenci. Hladiny IFX z pupečníkové krve byly měřeny pomocí metody ELISA. Výsledky: Do studie bylo zařazeno 20 těhotných žen (16 s Crohnovou nemocí, 4 s ulcerózní kolitidou) průměrného věku 28,7 ± 4,1 let, z nich 55 % (11) bylo prvorodiček. Střední doba trvání onemocnění k počátku těhotenství byla 6,0 ± 5,3 let, 70 % (14) žen mělo anamnézu perianálního postižení. V období početí trpělo 30 % (6) žen aktivní chorobou, 65 % (13) bylo v remisi a u jedné pa cientky byla nově dia g...

show abstract

Section: Ifx Ther Apymentioning

confidence: 99%